Approaches to preventative and therapeutic HIV vaccines

Flynn, 2005, Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection, J Infect Dis, 191, 654, 10.1086/428404 Pitisuttithum, 2006, Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand, J Infect Dis, 194, 1661, 10.1086/508748 Mascola, 1996, J Infect Dis, 173, 340, 10.1093/infdis/173.2.340 Haynes, 2014, Redemption of autoreactive B cells, Proc Natl Acad Sci U S A, 111, 9022, 10.1073/pnas.1407877111 Gilbert, 2005, Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial, J Infect Dis, 191, 666, 10.1086/428405 Tongo, 2014, Challenges in the design of a T cell vaccine in the context of HIV-1 diversity, Viruses, 6, 3968, 10.3390/v6103968 Duerr, 2012, Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study), J Infect Dis, 206, 258, 10.1093/infdis/jis342 Gray, 2011, Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study, Lancet Infect Dis, 11, 507, 10.1016/S1473-3099(11)70098-6 Moodie, 2015, Continued follow-up of phambili phase 2b randomized HIV-1 vaccine trial participants supports increased HIV-1 acquisition among vaccinated men, PLoS One, 10, e0137666, 10.1371/journal.pone.0137666 Gray, 2014, Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study, Lancet Infect Dis, 14, 388, 10.1016/S1473-3099(14)70020-9 Li, 2011, Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study, PLoS One, 6, e20479, 10.1371/journal.pone.0020479 Letvin, 2011, Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys, Sci Transl Med, 3, 81ra36, 10.1126/scitranslmed.3002351 Churchyard, 2011, A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204), PLoS One, 6, e21225, 10.1371/journal.pone.0021225 Hammer, 2013, Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine, N Engl J Med, 369, 2083, 10.1056/NEJMoa1310566 Williams, 2015, HIV-1 Vaccines. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies, Science, 349, aab1253, 10.1126/science.aab1253 Roederer, 2014, Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV, Nature, 505, 502, 10.1038/nature12893 Rerks-Ngarm, 2009, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand, N Engl J Med, 361, 2209, 10.1056/NEJMoa0908492 McElrath, 2008, HIV-1 vaccine-induced immunity in the test-of-concept step study: a case–cohort analysis, Lancet, 372, 1894, 10.1016/S0140-6736(08)61592-5 Nitayaphan, 2004, Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults, J Infect Dis, 190, 702, 10.1086/422258 Haynes, 2012, Immune-correlates analysis of an HIV-1 vaccine efficacy trial, N Engl J Med, 366, 1275, 10.1056/NEJMoa1113425 Corey, 2015, Immune correlates of vaccine protection against HIV-1 acquisition, Sci Transl Med, 7, 310rv317, 10.1126/scitranslmed.aac7732 Liao, 2013, Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2, Immunity, 38, 176, 10.1016/j.immuni.2012.11.011 Gray, 2014, HVTN 097: Evaluation of the RV144 vaccine regimen in HIV uninfected South African adults, AIDS Res Hum Retroviruses, 30SI, A33, 10.1089/aid.2014.5052a.abstract Fuchs, 2015, Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals, J AIDS Clin Res, 6, 10.4172/2155-6113.1000461 Ringe, 2015, Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers, J Virol, 89, 12189, 10.1128/JVI.01768-15 Wu, 2012, Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site, J Virol, 86, 5844, 10.1128/JVI.07139-11 Ledgerwood, 2015, Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults, Clin Exp Immunol, 182, 289, 10.1111/cei.12692 Ensoli, 2014, Challenges in HIV vaccine research for treatment and prevention, Front Immunol, 5, 417, 10.3389/fimmu.2014.00417 Garcia, 2012, Therapeutic vaccines against HIV infection, Hum Vaccin Immunother, 8, 569, 10.4161/hv.19555 Cafaro, 2015, Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine, Expert Opin Biol Ther, 15, S13, 10.1517/14712598.2015.1021328 Krone, 1988, Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo, J Med Virol, 26, 261, 10.1002/jmv.1890260306 Reiss, 1989, Seroconversion to HIV-1 rev- and tat-gene-encoded proteins, AIDS, 3, 105, 10.1097/00002030-198902000-00010 Ensoli, 2006, Candidate HIV-1 Tat vaccine development: from basic science to clinical trials, AIDS, 20, 2245, 10.1097/QAD.0b013e3280112cd1 Rezza, 2005, The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters, J Infect Dis, 191, 1321, 10.1086/428909 Bellino, 2014, The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study, Retrovirology, 11, 49, 10.1186/1742-4690-11-49 Bellino, 2009, Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate, Rev Recent Clin Trials, 4, 195, 10.2174/157488709789957529 Ensoli, 2009, The preventive phase I trial with the HIV-1 Tat-based vaccine, Vaccine, 28, 371, 10.1016/j.vaccine.2009.10.038 Longo, 2009, Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up, Vaccine, 27, 3306, 10.1016/j.vaccine.2009.01.090 Ensoli, 2010, Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART, PLoS One, 5, e13540, 10.1371/journal.pone.0013540 Ensoli, 2015, HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial, Retrovirology, 12, 33, 10.1186/s12977-015-0151-y Caskey, 2015, Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117, Nature, 522, 487, 10.1038/nature14411 Lynch, 2015, Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection, Sci Transl Med, 7, 319ra206, 10.1126/scitranslmed.aad5752